Intravenous immunoglobulin treatment in peripheral nerve disorders - indications, mechanisms of action and side-effects

被引：18

作者：

Hahn, AF ^{[1
]}

机构：

[1] Univ Western Ontario, London Hlth Sci Ctr, London, ON N6A 5A5, Canada

来源：

CURRENT OPINION IN NEUROLOGY | 2000年 / 13卷 / 05期

关键词：

D O I：

10.1097/00019052-200010000-00012

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

This review summarizes observations of clinical use of high dose intravenous immunoglobulin G (IVlg) in regards to administration, kinetics, known or postulated mechanisms of action, and adverse reactions. Indications and value of IVlg for the treatment of various neuropathies with presumed autoimmune aetiology are examined. New knowledge that advances the understanding of the pathogenesis of the neuropathies and of the mechanisms of action of IVIg is discussed. Curr Opin Neurol 13:575-582 (C) 2000 Lippincott Williams & Wilkins.

引用

页码：575 / 582

页数：8

共 97 条

[1]

Ahsan N, 1998, J NEPHROL, V11, P157

[2] Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies [J].

Ang, CW ;

Yuki, N ;

Jacobs, BC ;

Koga, M ;

Van Doorn, PA ;

Schmitz, PIM ;

Van der Meché, FGA .

NEUROLOGY, 1999, 53 (09) :2122-2127

[3] THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN MILLER FISHER SYNDROME [J].

ARAKAWA, Y ;

YOSHIMURA, M ;

KOBAYASHI, S ;

ICHIHASHI, K ;

MIYAO, M ;

MOMOI, MY ;

YANAGISAWA, M .

BRAIN & DEVELOPMENT, 1993, 15 (03) :231-233

[4] INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN PATIENTS WITH MOTOR-NEURON SYNDROMES ASSOCIATED WITH ANTI-GM1 ANTIBODIES - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].

AZULAY, JP ;

BLIN, O ;

POUGET, J ;

BOUCRAUT, J ;

BILLETURC, F ;

CARLES, G ;

SERRATRICE, G .

NEUROLOGY, 1994, 44 (03) :429-432

[5] Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis [J].

Basta, M ;

Illa, I ;

Dalakas, MC .

JOURNAL OF NEUROIMMUNOLOGY, 1996, 71 (1-2) :227-229

[6] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN EXERTS ITS BENEFICIAL EFFECT IN PATIENTS WITH DERMATOMYOSITIS BY BLOCKING ENDOMYSIAL DEPOSITION OF ACTIVATED COMPLEMENT FRAGMENTS [J].

BASTA, M ;

DALAKAS, MC .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) :1729-1735

[7] Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming [J].

Berkovitch, M ;

Dolinski, G ;

Tauber, T ;

Aladjem, M ;

Kaplinsky, C .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1999, 21 (06) :411-415

[8]

Bertorini TE, 1996, MUSCLE NERVE, V19, P388, DOI 10.1002/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO

[9]

2-N

[10] Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase [J].

Bleeker, WK ;

Teeling, JL ;

Verhoeven, AJ ;

Rigter, GMM ;

Agterberg, J ;

Tool, ATJ ;

Koenderman, AHL ;

Kuijpers, TW ;

Hack, CE .

BLOOD, 2000, 95 (05) :1856-1861

← 1 2 3 4 5 6 7 8 9 10 →